Stories

Prime Therapeutics named a 2021 Best and Brightest in Wellness winner

Prime is one of 35 U.S. companies honored for its commitment to employee health and wellness

August 26, 2021
Prime Therapeutics (Prime) was recently honored as a Best and Brightest in Wellness award recipient by the National Association for Business Resources. This program honors companies that promote employee well-being and workplace health and wellness.

“Prime values the health and wellness of our employees, so we are honored to be named as a Best and Brightest in Wellness award recipient,” says Kerry Florian, vice president, total rewards. “It’s great to see that our wellness offerings help employees flourish both at work and in their personal lives.”

Prime was named one of the recipients based on best practices around health and wellness, including wellness participation and incentives, benefits and programs, leadership, employee input, culture, and workplace environment.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization serving health plans, employers and government programs. Prime is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. Magellan Rx Management LLC, a Prime Therapeutics LLC Company, is a pioneer in specialty and medical drug management and a leader in serving public sector state government programs. Together Prime and Magellan Rx provide a wide range of clients with solutions that bridge the distance between medical and pharmacy management. For more information visit primetherapeutics.com and magellanrx.com or follow us on X (Twitter) at @Prime_PBM and @Magellan_Rx.

Related news

Stories

July 22, 2024

Introducing the latest issue of our medical and pharmacy benefit management report

The summer 2024 issue of the Magellan Rx Report provides insights on the industry’s most groundbreaking managed care solutions in some of the most complex areas of health care

Read More

Stories

July 18, 2024

Specialty drug trend forecasted to drop for employer groups, clinical experts say

Introduction of Humira® and Stelara® biosimilars contribute to continued decline in the autoimmune – anti-inflammatory trend

Read More

Stories

July 16, 2024

Prime/Magellan Rx earns top score on the Disability Equality Index

For the second consecutive year, Prime Therapeutics/Magellan Rx Management received a score of 100 on the Disability Equality Index®, which benchmarks disability workplace inclusion

Read More
View all news